Quick Answer
Inhibrx Biosciences, Inc. reported Total Assets of $146.48 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $146.48M | -19.0% |
| 2024 | $180.77M | -41.3% |
| 2023 | $307.89M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $177.47M | -20.3% | -16.3% |
| June 30, 2025 | $212.12M | -17.9% | -12.6% |
| March 31, 2025 | $242.64M | — | +34.2% |
| December 31, 2024 | $180.77M | -41.3% | -18.8% |
| September 30, 2024 | $222.56M | — | -13.9% |
| June 30, 2024 | $258.42M | — | -16.1% |
| December 31, 2023 | $307.89M | — | — |
- Inhibrx Biosciences, Inc. showed a decrease of -19.0% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s total assets has declined by 52.4% (from $307.89 million to $146.48 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: